Survival and quality of Life for children with end-stage heart failure who are not candidates for cardiac transplant

被引:2
|
作者
Sabati, Arash Alen [1 ]
Szmuszkovicz, Jacqueline R. [1 ]
Herrington, Cynthia [2 ]
Hermes, Mark [1 ]
Mahmoud, Hesham A. [1 ]
Wee, Choo Phei [3 ]
Starnes, Vaughn A. [2 ]
Menteer, JonDavid [1 ]
机构
[1] Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Div Cardiol, Los Angeles, CA USA
[2] Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Dept Cardiothorac Surg, Los Angeles, CA USA
[3] Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Clin Invest Ctr,Saban Res Inst, Los Angeles, CA USA
来源
关键词
Pediatric heart failure; pediatric heart transplant; congenital heart disease; congenital heart surgery; alloimmunization; panel reactive antibodies; OUTCOMES;
D O I
10.1016/j.healun.2015.01.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Some pediatric patients referred for heart transplant (HTx) are sub-optimal candidates. Their outcomes without HTx are presumed to be dismal, but have not been well described. Knowledge about their outcomes is critical when weighing the risks between a high-risk transplant and "terminal" palliation. METHODS: We retrospectively reviewed all HTx referrals from January 2005 to July 2013. We excluded those who were listed for HTx, or who were denied HTx due to being "too well," seeking only those who were in need of but not suitable for HTx. End-points included mortality and length of survival. RESULTS: Of 212 referrals, 39 (19%) (age 0 to 19 years, median 3.5 years) were denied HTx for reasons other than being too well. Twenty-eight (72%) had palliated congenital heart disease. Overall mortality during the follow-up period was 38% (n = 15) with a median follow-up time of 195 days (8 to 2,832 days). Ten patients received subsequent cardiac surgery with 1 death (10%) and median follow-up of 2.6 years. Mortality risk was not influenced by age, weight, growth failure, congenital heart disease or single-ventricle physiology. Mechanical ventilation (hazard ratio 6.31, p = 0.001) and inotrope dependence (hazard ratio 4.79, p = 0.006) were associated with the highest risk of mortality. Quality of life was measured with the PedsQL cardiac module and completed by 11 of 16 eligible patients with an overall average score of 70.2 +/- 23.9. CONCLUSIONS: An advanced heart failure program can achieve satisfactory results for pediatric patients who are not suitable candidates for HTx. For some children, high-risk palliative surgery can result in better outcome than high-risk HTx. Mortality was related to the degree of heart failure at presentation rather than underlying heart disease. (C) 2015 International Society for Heart and Lung Transplantation. All rights reserved.
引用
收藏
页码:906 / 911
页数:6
相关论文
共 50 条
  • [1] Longitudinal quality of life assessment in patients with end-stage heart failure before and after cardiac transplant
    Riedmayr, MI
    Tammen, AR
    Wittig, C
    Uberfuhr, P
    Bullinger, M
    Reichart, B
    Angermann, CE
    QUALITY OF LIFE RESEARCH, 1997, 6 (7-8) : 318 - 318
  • [2] End-stage heart failure: quantity or quality of life?
    Delahaye, F
    Mercusot, A
    Carra, L
    Gouton, M
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 2005, 98 (03): : 186 - 191
  • [3] End-stage heart failure and heart transplant in cardiac sarcoidosis: a case series
    Scuppa, Maria Francesca
    Accietto, Antonella
    Corsini, Anna
    Graziosi, Maddalena
    Biagini, Elena
    Baldovini, Chiara
    Sabatino, Mario
    Potena, Luciano
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2024, 8 (12)
  • [4] Experience of patients with end-stage heart failure who underwent heart transplant at UCLA
    Hachida, M
    Nonoyama, M
    Miyagishima, M
    Hoshi, H
    Iwade, K
    Matsuda, N
    Saito, S
    Hosoda, S
    Koyanagi, H
    Laks, H
    HEART AND VESSELS, 1997, : 34 - 36
  • [5] End-Stage Heart Failure in Cardiac Sarcoidosis
    Velikanova, Diana
    Poyhonen, Pauli
    Lehtonen, Jukka
    Simonen, Piia
    Uusitalo, Valtteri
    Vihinen, Tapani
    Kaikkonen, Kari
    Haataja, Petri
    Kerola, Tuomas
    Rissanen, Tuomas T.
    Vepsalainen, Ville
    Alatalo, Aleksi
    Pietila-Effati, Paivi
    Kupari, Markku
    CIRCULATION, 2024, 149 (11) : 885 - 887
  • [6] End-stage heart failure: The future of heart transplant and artificial heart
    Bounader, Karl
    Flecher, Erwan
    PRESSE MEDICALE, 2024, 53 (01):
  • [7] Quality of life in end-stage renal failure
    Petrova, N
    QUALITY OF LIFE RESEARCH, 1997, 6 (7-8) : 280 - 280
  • [8] Skeletal Muscle Index and Malnutrition in Children With End-Stage Heart Failure Awaiting Heart Transplant
    Schultz, Lisa M.
    Larson, David
    Isaacson, Jared
    Dennis, Katelin
    Rosenthal, David N.
    Dykes, John C.
    Liu, Esther
    Zhang, Yulin
    McElhinney, Doff B.
    Almond, Christopher S.
    CIRCULATION, 2017, 136
  • [9] Pleural Effusion in Patients With End-Stage Liver Disease Who Are Candidates For Transplant
    Dogrul, Mustafa Ilgaz
    Akcay, Sule
    Bozbas, Serife Savas
    Dedekarginoglu, Balam Er
    Eyuboglu, Fasun Oner
    Moray, Gokhan
    Haberal, Mehmet
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2014, 12 : 149 - 152
  • [10] Haemodynamic profiles of children with end-stage heart failure
    Chen, Sharon
    Dykes, John C.
    McElhinney, Doff B.
    Gajarski, Robert J.
    Shin, Andrew Y.
    Hollander, Seth A.
    Everitt, Melanie E.
    Price, Jack F.
    Thiagarajan, Ravi R.
    Kindel, Steven J.
    Rossano, Joseph W.
    Kaufman, Beth D.
    May, Lindsay J.
    Pruitt, Elizabeth
    Rosenthal, David N.
    Almond, Christopher S.
    EUROPEAN HEART JOURNAL, 2017, 38 (38) : 2900 - 2909